INDUCE-1: Report on safety run-in cohorts combining Inducible T-cell co-stimulatory receptor agonist GSK3359609 with platinum+5-FU chemotherapy with or without pembrolizumab for the treat...

INDUCE-1: Report on safety run-in cohorts combining Inducible T-cell co-stimulatory receptor agonist GSK3359609 with platinum+5-FU chemotherapy with or without pembrolizumab for the treat...

User Photo
Cancer-News

3 weeks
42 Views
Share
Want to watch this again later?
Sign in to add this video to a playlist. Login
0 0
Category:
Description:

Erminia Massarelli, MD City of Hope discusses INDUCE-1: Report on safety run-in cohorts combining Inducible T-cell co-stimulatory receptor (ICOS) agonist GSK3359609 (GSK609) with platinum+5-FU chemotherapy (5-FU/plat), with or without pembrolizumab (PE), for the treatment of advanced solid tumorsASCOhttps://meetinglibrary.asco.org/record/184678/abstract

Up Next Autoplay